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inhalants such as fragrances, traffic exhaust, foods, drugs, alcohol, and caffeine. Although anecdotal clinical evidence supports this hypothesis, carefully conducted epidemiologic and experimental studies are needed for its corroboration or rejection.
A series of research questions designed to test the two-step mechanism proposed above was devised. While other working groups focused on conditioning and learning, psychoneuroimmunology, neurogenic inflammation, and neural sensitization as possible explanations for chemical sensitivity, the Working Group on Toxicant-induced Loss of Tolerance developed an approach to test directly the relationship between specific exposures and patients' reported symptoms and physiological responses.
Double-blind, placebo-controlled human challenge studies are essential to understand the nature of chemical sensitivity.
Research focusing on exploring particular mechanisms while excluding others at this early stage of scientific investigation could lead to blind alleys. Pivotal questions about the origins of the condition, such as the role of chemical exposures compared to that of individual perception, may remain unanswered. In the tradition of scientific inquiry, research in this area should proceed from the general to the specific. Once the general nature of chemical sensitivity is understood (e.g., toxigenic, psychogenic), particular mechanisms can be explored. Scarce resources must not be expended on intriguing but irrelevant hypotheses.
Defining whether chemical sensitivity is physiological in origin or psychogenic is important for many reasons, including policy setting, prevention, and selection of appropriate therapies. However, investigators in this area must be cautious in interpreting their experimental observations because subjects' responses to challenges may involve both physiological and psychological elements. For example, psychological symptoms such as depression or irritability may be psychogenic or organically based, or both. Subjects who fail to respond to active challenges may respond differently under other circumstances. Blinding odorous substances is a task subject to numerous pitfalls.
Several terms were defined. Loss of tolerance is defined as the loss of natural or native tolerance for common substances such as fragrances, traffic exhaust, foods, caffeine, or alcoholic beverages. The term refers to the reported finding that some persons exhibit adverse reactions to chemicals that they formerly did not exhibit and that others do not exhibit at the doses or levels administered. This definition is in contrast to acquired tolerance, e.g., to a drug, which is defined as reduced effect as a function of dosage. Masking, discussed in detail by Miller (6) For all subjects, the EMU experience would begin with a period of controlled exposure. To assure that subjects were at a clean baseline (unmasked) before testing, they would be housed in a hospital research area or a wing specially designed to reduce exposure to volatile organic chemicals, an EMU (1, 7, 8 Following the 4-to 7-day period of unmasking, blinded challenges should be conducted using the same incitants used at admission. This approach to testing subjects-both on entry into the EMU and after unmasking-could help advance understanding of the possible effects of masking upon responses. Ideally there should be no contact between subjects before or during testing; however, this would be very difficult to achieve. The wisest option might be to house subjects together but test them separately.
Statistical considerations are important in determining the number of repeat challenges per incitant. Also, there are practical limits as to the number of challenges patients can be expected to undergo, particularly if their symptoms are severe. Careful consideration should be given to reacclimatizing subjects to real-world conditions on completion of their evaluation and before discharge from the EMU. A protocol might be designed for this purpose that consists of gradual reintroduction of less problematic triggers.
Even among chemically sensitive persons exhibiting highly individualized symptoms in response to many different incitants, it may be possible to study and compare subjects and controls in an informative way. Before subjects enter the EMU, baseline challenges could be conducted to characterize each subject's incitants and symptoms. Incitants such as formaldehyde or ethanol that are common to several groups of subjects may help define subgroups, as may particular symptoms such as breathing difficulties or gastrointestinal effects.
During the double-blind, placebo-controlled challenges, patients could be asked to report the severity of their symptoms on a scale (e.g., a 10-point scale) that Substances known to bioaccumulate such as polychlorinated biphenyls and chlordane should not be used for testing. The ethics of using certain common household pesticides even at very low concentrations as challenge substances was discuessed. Some reports suggest that certain pesticides might initiate chemical sensitivity in susceptible persons (4, 9) . Another consideration is the length of studies and cost involved in waiting 4 to 7 days between challenges of a particular type. Chemically distinct challenges could be administered in the intervals between challenges of a given type provided subjects had recovered fully before each challenge.
Dependent Variables
Dependent variables discussed for possible use include: duration of response; symptoms such as headache, fatigue, myalgias, and other symptoms rated on visual analog scales to record severity; ratings on mood scales such as the Profile of Mood States (POMS); performance, which includes such things as computer-administered cognitive batteries (with emphasis on attention span, memory, and concentration measures) and balance (posturography); physiological measures which include nasal resistance, pulmonary function testing such as peak flow readings and FEV1, blood pressure, pulse, electrocardiogram, and galvanic skin response; and rheumatological indices such as rings for measuring finger joint swelling and dolorimeter readings for measuring pain.
Brief batteries for specific tasks could be alternated with continuous performance tasks. The duration of any testing sequence should not exceed about 20 min to be useful for administration before and after challenges.
As a practical matter, initial studies should focus on documenting signs and symptoms in response to blinded challenges, rather than costly shot-in-the-dark attempts to find blood markers or perform brain imaging.
Ethical Considerations Involving Human Subjects
Subjects should be counseled about the initial withdrawal or unmasking phase of their evaluation and challenge testing during which symptoms temporarily may increase in severity. On-site emergency response capabilities and limitations should be explained to subjects. If they are found to be sensitive to particular chemicals or foods during the study, a transitional "safety net" for reentry into the "real world" should be incorporated into the protocol. Upon completion of the study, participants should receive any data pertinent to their wellbeing, including the results of all challenges, how to avoid substances to which they reacted, and how to use air filters and/or respirators if indicated. As with all research involving human subjects, informed consent is required. The consent should fulfill social responsibility yet avoid biasing subjects' responses.
The masking hypothesis, the second question suggested for investigation, could be tested using an approach similar to that discussed in question 1. In this case, however, subjects in the EMU would be challenged with incitants already known to provoke significant effects. Changes in the intensity and duration of symptoms with sequential challenges administered at varying intervals-for example, 10 
